March 15, 2019 07:26 AM EDTUpdated December 10, 10:25 AM
Financing

South Ko­re­an in­ves­ti­ga­tors raid stock ex­change in an­oth­er Sam­sung Bi­o­Log­ics IPO probe — re­port

Natalie Grover

Reporter

Sam­sung’s biotech arm is in trou­ble, again. Pros­e­cu­tors re­port­ed­ly raid­ed the of­fice of the Ko­rea Ex­change — the bourse on which Sam­sung Bi­o­Log­ics list­ed in 2016 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times